Gene therapy patients tracked for 15 years in groundbreaking Follow-Up

NCT ID NCT07527975

First seen Apr 19, 2026 · Last updated Apr 19, 2026

Summary

This study follows patients who previously received an experimental gene therapy (RP-L102) for Fanconi anemia, a rare genetic disorder that affects bone marrow. Researchers will monitor 14 participants for up to 15 years to check long-term safety, see if the treatment effect lasts, and track blood counts and cancer risks. The goal is to understand if this one-time gene therapy can provide lasting control of the disease without needing a bone marrow transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FANCONI ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hospital Infantil Universitario Niño Jesús

    Madrid, 28009, Spain

  • Lucille Packard Children's Hospital, Stanford University

    Palo Alto, California, 94305, United States

  • University College London Great Ormond Street Institute of Child Health (GOSH)

    London, WC1N 1EH, United Kingdom

Conditions

Explore the condition pages connected to this study.